🇺🇸 FDA
Patent

US 8361710

MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21

granted A61PA61P35/00

Quick answer

US patent 8361710 (MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P35/00